Pego la parte interesante del artículo
The proposal would get at a tactic used by some drugmakers that allowed Mylan to
overcharge U.S. taxpayers by as much as $1.27 billion over the last decade by classifying the EpiPen as a generic drug rather than a brand-name treatment. Generic drugs provide lower discounts than their brand-name counterparts for Medicaid.
The president also talked about letting consumers import drugs from other countries with lower prices. Neither of those policies, which would likely require a change in law to be implemented in a meaningful way, are in drafts of the orders, according to one person familiar with the effort.
The FDA has already
outlined some policies to target drug pricing. Gottlieb has said the agency may
push new generic-drug applications to the front of the line in cases where there are fewer than three competing generic manufacturers, which could raise competition and lower costs for some treatments.
«Después de nada, o después de todo/ supe que todo no era más que nada.»